Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Pharmacol Ther. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16.

Pharmacogenetics: from bench to byte--an update of guidelines.

Author information

1
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

PMID:
21412232
DOI:
10.1038/clpt.2011.34
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center